Genmab A/S Announces Share Buy-back Program Update
Ticker: GNMSF · Form: 6-K · Filed: Jun 10, 2025 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Jun 10, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, sec-filing, company-update
TL;DR
Genmab A/S filed a 6-K on June 10, 2025, detailing share buy-back program transactions.
AI Summary
On June 10, 2025, Genmab A/S announced transactions related to its share buy-back program. The company is filing this report on Form 6-K to provide updates on these activities. This filing is incorporated by reference into Genmab's existing S-8 registration statements.
Why It Matters
This filing provides transparency on Genmab's ongoing share repurchase activities, which can impact share price and investor perception.
Risk Assessment
Risk Level: low — The filing is a routine update on a share buy-back program and does not contain significant new financial or operational risks.
Key Players & Entities
- Genmab A/S (company) — Registrant
- June 10, 2025 (date) — Filing date and announcement date
- 001-38976 (other) — SEC File Number
- 333-232693 (other) — S-8 Registration Statement File Number
- 333-253519 (other) — S-8 Registration Statement File Number
- 333-262970 (other) — S-8 Registration Statement File Number
- 333-277273 (other) — S-8 Registration Statement File Number
- 333-284876 (other) — S-8 Registration Statement File Number
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K filing is to report on transactions in connection with Genmab A/S's share buy-back program, as announced on June 10, 2025.
When was the company announcement regarding the share buy-back program made?
The company announcement regarding the share buy-back program was dated June 10, 2025.
Which SEC registration statements will this filing be incorporated into?
This filing will be incorporated by reference into Genmab A/S's registration statements on Form S-8, specifically File Numbers 333-232693, 333-253519, 333-262970, 333-277273, and 333-284876.
What is Genmab A/S's principal executive office address?
Genmab A/S's principal executive offices are located at Carl Jacobsens Vej 30, 2500 Valby, Denmark.
What type of report is this filing?
This filing is a Form 6-K, which is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 10, 2025 regarding GENMAB A/S (GNMSF).